VHT – Morgans rates the stock as Add
The broker adopts a changed valuation method and raises its target price to $1.94 from $1.87. Add retained.
Read MoreTag: VHT
VHT – Morgans rates the stock as Add
Morgans makes no changes to forecasts and retains its Add rating and $1.87 target price after Volpara Health Technologies reported a “solid” 2Q result.
Read MoreNext generation breast cancer screening
Presenter – Ralph Highnam – CEO – Volpara Health provides clinically validated, AI-powered software for personalized screening and early detection of breast cancer.
Read MoreVHT – Morgans rates the stock as Add
Via the recent CRA Health acquistion, Volpara Health Technologies has announced its largest contract to date worth over US$400,000 per annum. The Add rating is maintained and the target price is increased to $1.94 from $1.92.
Read MoreVHT – Morgans rates the stock as Add
Volpara Health Technologies has completed a strategic acquisition of CRA Health, a Boston based breast cancer risk assessment company. Morgans’ add rating is maintained and the target price is increased to $1.92 from $1.70.
Read MoreVHT – Morgans rates the stock as Add
Volpara Health Technologies posted a third quarter cashflow report in-line with the expectations of Morgans. The add rating is maintained and the target price is decreased to $1.70 from $1.71.
Read MoreVHT – Morgans rates the stock as Add
Volpara Health Technologies has signed a five-year SaaS contract with BreastScreen Queensland for the quality assurance platform, VolparaEnterprise. Morgans makes no changes to forecasts, and the Add rating and target price of $1.71 are unchanged.
Read MoreVolpara Health Technologies (ASX: VHT) – Hidden Gems Webinar Presentation
Presenter – Ralph Highnam – CEO – Volpara is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. Volpara’s clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice software management helps with productivity, compliance, reimbursement, and patient tracking.
Read More2020 Picks Of The Year: But How Did 2019 Pick’s Go?
It’s that time of the year again where predictions are made for 2020 and before embarking on those, I always think it is worth reviewing last year’s key ideas
Read MoreVolpara Acquisition Accelerates Future Growth
Volpara Health (VHT) has been a stock that I have highlighted a couple of times, including at the start of the year where it was one of the few companies that was attractive according to my strict stock selection process. This week the company raised $55 million to acquire MRS Systems in the United States and accelerate their sales team and market penetration.
Read MoreVolpara Health: Becoming The Industry Standard
VHT is right up there with my favourite stocks not just for 2019 but for years to come as it is one of the few times where I can truly say I have confidence in their business, their product and the industry – a change from an alternative to the standard.
Read More2019’s Best Trades: Bonds, Stocks, Aussie Dollar & Tesla
At the start of every calendar year, everyone asks anyone what their best picks for the year are. Naturally, “best picks” usually refers to those ideas that will generate the biggest return but little if no attention is given to the volatility or the risk of that idea over the course of the year.
Read More